A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, which could make precision medicine more effective for patients with a highly resistant form of lung cancer. The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C mutation—a driver in about 14% of non-small cell lung cancers.
Leave A Comment